Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Racura OncologyASX:RAC +2.27%29 Revenue per Share is A$0.00 as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 29/100. Among 767 Biotechnology companies, Racura Oncology ranks worse than 130377.97% on this metric.
Racura Oncology's revenue per share for the
six
months ended in Dec. 2025 was A$0.00.
Racura Oncology's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Racura Oncology's Revenue per Share or its related term are showing as below:
ASX:RAC's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Racura Oncology Revenue per Share Related Terms
Racura Oncology Revenue per Share Historical Data
* Premium members only.
The historical data trend for Racura Oncology's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAC vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, Racura Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Racura Oncology's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Racura Oncology's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Racura Oncology (ASX:RAC) has a Revenue per Share of A$0.00 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #999999 out of 767 companies in the Biotechnology industry.
Is Racura Oncology's Revenue per Share too high?
Racura Oncology's current Revenue per Share is A$0.00. Based on the distribution chart, Racura Oncology ranks #999999 out of 767 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #999999 out of 767 companies for Revenue per Share. This places Racura Oncology in the lower half of its industry. The industry median Revenue per Share is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.00, based on 767 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Racura Oncology and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current Revenue per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Revenue per Share of A$0.00. The current Revenue per Share is A$0.00. Racura Oncology's overall GF Score™ is 29/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Revenue per Share is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
29GF Score
Get the complete analysis for ASX:RAC
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
